Business Wire

Open Connectivity Foundation Brings Massive Scale to IoT Ecosystem

Del

Today, major industry leaders who are invested in the future of the Internet of Things, announced they will unify as the Open Connectivity Foundation (OCF), an entity whose goal will be to help unify IoT standards so that companies and developers can create IoT solutions and devices that work seamlessly together. Via cross-industry collaboration, the OCF will work towards unlocking the massive opportunity of the future global IoT segment, accelerate industry innovation and help all developers and companies create solutions that map to a single, open IoT interoperability specification. Ultimately, with OCF specifications, protocols and open source projects, a wide-range of consumer, enterprise and embedded devices and sensors from a variety of manufacturers, can securely and seamlessly interact with one another.

The OCF unifies the entirety of the former Open Interconnect Consortium with leading companies at all levels – silicon, software, platform, and finished-goods – dedicated to providing this key interoperability element of an IoT solution.

The OCF’s vision for IoT is that billions of connected devices (appliances, phones, computers, industrial equipment) will communicate with one another regardless of manufacturer, operating system, chipset or transport. With the OCF fulfilling this promise, anyone – from a large technology company to a maker in their garage - can adopt the open standards of OCF to innovate and compete, helping ensure secure interoperability for consumers, business, and industry.

About Open Connectivity Foundation

Billions of connected devices (devices, phones, computers and sensors) should be able to communicate with one another regardless of manufacturer, operating system, chipset or physical transport. The Open Connectivity Foundation (OCF) is creating a specification and sponsoring an open source project to make this possible. OCF will unlock the massive opportunity in the IoT market, accelerate industry innovation and help developers and companies create solutions that map to a single open specification. OCF will help ensure secure interoperability for consumers, business, and industry. For more information, please visit www.openconnectivity.org.

Supporting Quotes

ARRIS

“We are excited to be a part of this revolutionary group of leaders and look forward to bringing a standardized and powerful solution to both Service Providers and Retail as more devices and IoT services enter the market.” – Charles Cheevers, CTO, Customer Premises Equipment.

CableLabs

“CableLabs is all about interoperability and scale economics. We are extremely supportive of the unification of these efforts and believe that it will allow the broader industry to better leverage their equipment, services and infrastructure. This greatly expands the Internet of Things footprint for cable operators, their suppliers, and most importantly their subscribers.” – Ralph Brown, Chief Technology Officer

Cisco

"OIC’s leadership and expansion to OCF is a step forward as these two leading standards bodies are unified to achieve a common set of protocols and certifications for IoT. OCF will help enable developers and industries around consumer, SP, enterprise, industrial to leverage promise of IoT in a scalable and secure manner.” – John Oberon, Vice President, IoT Software

Electrolux

“The Open Connectivity Foundation will create significant value for consumers by paving the way for an interoperable future. We’re well on our way to a truly smart home, and this will only happen when appliances can freely communicate with a wide range of products. This important move takes us one step closer to realizing that vision, by widening our existing collaboration initiatives to an even larger number of global brands.” -- Jan Brockmann, Chief Operations Officer

GE Digital

“Breaking down the barriers of technology silos and supporting better integration of these solutions and devices will be key to advancing the Industrial Internet of Things. GE is excited to join together with other organizations to create the standards that will help enable interoperability in the future.” – Greg Petroff, Chief Experience Officer

Intel

“We believe in a future where all of the devices in our lives are connected to enable ways of living and working that we can’t even imagine today. The only way to unlock the unlimited possibilities for innovation in the Internet of Things is to unify our work with industry peers. This collaboration is an exciting step in that direction.” – Doug Fisher, Senior Vice President and General Manager, Software and Services Group

Microsoft

“The OCF will help consolidate industry attention and create opportunity, via an agreed upon set of protocols that move the world forward. We are designing Windows 10 to be the ideal operating system and Azure to be the best cloud companion for Things, and for both of them to interoperate with all Things. Windows 10 devices will natively support the new OCF standard, making it easy for Windows to discover, communicate, and orchestrate multiple IoT devices in the home, in business, and beyond. We look forward to seeing the innovation this new standard will enable for all customers and the endless opportunities it will create for developers.” – Terry Myerson, EVP, Windows and Devices Group

Qualcomm

“Qualcomm has pursued the goal of open interoperability from the beginning. We helped develop the AllJoyn framework to drive this goal, and now we look forward to collaborating with leading IoT-focused companies to form the OCF for precisely the same reason. We look forward to achieving the IoT vision we all share.” – Michael Wallace, President of Qualcomm Connected Experiences, Inc. (a subsidiary of Qualcomm Incorporated)

Samsung

"OIC has been working to develop a standard specification for IoT devices, and at the same time developing IoTivity as an open source reference implementation. We welcome these leaders in their fields to OCF, which we believe will become the most diverse global organization developing IoT standards and code." – SeungHwan Cho, Executive Vice President and Deputy Head of Software R&D Center

Contact information

Blanc & Otus for OCF
Danielle Tarp, +1 415-856-5182
Danielle.tarp@blancandotus.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom